New drug cocktail aims to replace chemo for lymphoma patients
NCT ID NCT07502872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of three drugs (polatuzumab vedotin, glofitamab, and tafasitamab) as a first-line treatment for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. The goal is to see if this chemo-free approach can shrink tumors and control the disease with fewer side effects. About 30 participants will receive the treatment, and researchers will monitor how many achieve a complete response and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Polatuzumab vedotin, glofitamab, and tafasitamab (drug combination)
- What this could lead to
- If successful, this could offer a chemotherapy-free first-line treatment option for certain types of B-cell lymphoma, potentially reducing side effects while controlling the disease.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 30 participants, so results may not apply broadly. The combination may cause serious side effects like cytokine release syndrome, and it is not expected to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?